STAT Plus: Tyme Technologies misleads with new data on pancreatic cancer drug
NIH
Tyme Technologies says new data show its pancreatic cancer drug “improves survival." But there are red flags, and the data fall below investor expectations.
Sols 4345-4347: Contact Science is Back on the Table
Hace 21 horas
.jpeg)
No hay comentarios:
Publicar un comentario